Almost all clinical psychedelic drug research is being affected in some way or another by COVID-19. But, response measures vary from one organization to the next.

As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”

In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.

The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.

“The Corona Virus is a necessary purge of what is no longer in resonance,” Trinity de Guzman wrote in a recent email to his followers.

A long-fought battle for access to peyote, and a dwindling population in the United States has led Native American Church members and peyote conservationists to request that peyote be left out of decriminalization efforts.

As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.

The new leaders of the psychedelic medicalization industry seem to see themselves as above their own self-proposed rules.

Many predicted an ethical storm brewing in the lead-up to the explosion of for-profit interest in psychedelic pharmaceuticals. But, were their efforts to mitigate the damage enough to make a difference?

Our statement on a recent Chacruna article by Dr. Bia Labate.

Could a liquid-delivery system meant to help maintain a personalized “scent bubble” quietly usher in the creation of wearable psychedelic microdosing technology? A U.S. patent for this system is just one among an increasing list of psychedelic-inspired intellectual properties.

Psychedelic advocates have long asserted that broader psychedelic use will lead to a more open, progressive society, but there are too many instances of right-wingers who have taken them for that to be true.

A recent BBC story entitled “The ‘psychedelics coach’ with drug-fuelled career advice,” offers an opportunity to examine what happens when sloppy journalism and self-promotional psychedelic marketers collide.

Pinchbeck has not publicly engaged in the difficult work of reorganizing his relationship to power, which is a precondition for learning to wield power and authority responsibly. Instead, he has shown that he is predominantly concerned with reestablishing his career and with recentering himself as an authority figure

With a checkered history of misconduct, how will psychedelic-assisted therapists be held accountable in the emerging legal field?

With the recent creation of the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine in Baltimore, Maryland, we must remember that, while industrialized medicine has never attempted to serve all people, institutional histories vary from one organization to the next.

If we truly believe in the positive transformational power of visionary plant experiences, we must support each other to make real social change happen, less this transformation stagnates at the individual level.

After the murder of a Peruvian healer in 2018, traditional healers, local political figures, and nonprofit allies gathered to address the complexities that come with the influx of foreigners seeking ayahuasca in the Amazon.

Eight staff have quit The Third Wave and issued an open statement.

As psychedelic medicalization and the potential profits of a “virgin market” loom large, new organizations are increasingly looking to gain legitimacy within the field. Mainstreaming means the doors of this field are being thrown wide open.